No Data
No Data
[Brokerage Focus] Guosen Securities maintains a rating of outperform on Green Bamboo Biotech (02480), indicating a favorable competitive landscape for domestic herpes zoster vaccine products.
Jinwu Finance News | Guosen Securities issued research guidance, Green Bamboo Biotech (02480) reported an adjusted loss of 0.11 billion yuan in the first half of 2024, compared to a loss of 0.079 billion yuan in the same period last year. In the first half of 2024, research and development expenses were 0.08 billion yuan (+142.4% year-on-year), mainly due to the Phase 3 clinical trial of LZ901 in China; administrative expenses were 0.045 billion yuan (+9.0% year-on-year), mainly due to increased depreciation of properties, factories, and equipment due to the completion of certain construction projects. The bank pointed out that LZ901, a candidate vaccine for herpes zoster, is one of the company's core pipelines and is expected to become the world's first.
LUZHU BIOTECH-B: Interim Report 2024
Luzhu Biotech -B (02480) released its interim performance, with a net loss of 0.11 billion yuan, a year-on-year increase of 38.5%
Green Bamboo Biology-B (02480) announced its six-month performance ending on June 30, 2024, with other income of 973...
LUZHU BIOTECH-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
Green Bamboo Biotech -B (02480.HK) plans to hold a board of directors meeting on August 21 to approve its mid-year performance.
Chlorophyll Biology - B (02480.HK) announced on August 9 that the company will hold a board of directors meeting on Wednesday, August 21, 2024 to (including) consider and approve the unaudited comprehensive mid-term performance of the company and its subsidiaries for the six months ending June 30, 2024, and to consider the proposal of distributing mid-term dividends (if any).
Luzhu Bio-B (02480) bought back 3400 shares on July 16th.
Green Bamboo Biotech-B (02480) announced that it will spend HKD 0.083 million to repurchase 34... on July 16, 2024.
No Data
No Data